FT : Fears over a medical gold rush in cancer drug race

Fears over a medical gold rush in cancer drug race
With almost 800 trials under way observers warn scientific rigour is being compromised

It might sound like a strange complaint against an industry often accused of scrimping on research to fund marketing efforts, but some executives and scientists say drugmakers are doing too many clinical trials in the hot new field of immunotherapy.

Merck and Bristol-Myers Squibb have dominated the first wave of immunotherapy with their “checkpoint inhibitors”, which release brakes in the immune system so that it can attack tumours, while Roche, AstraZeneca and Pfizer are trying to catch up by launching rival versions. Almost $9bn worth of these checkpoints have been sold since they went on sale two years ago. 

Early enthusiasm for the medicines has given way to a determination to push response rates substantially higher. Although a minority of about 20 to 30 per cent of patients respond extremely well to the drugs — living for months or years longer than their doctors would expect — the majority derive no benefit. 

“There is some pushback,” said Jill O'Donnell-Tormey, chief executive of the Cancer Research Institute. “Are there too many trials? Are we just throwing spaghetti at the wall, by taking compound ‘X’ or ‘Y’ and adding it together just to see what happens?” 

Most scientists say checkpoints do not need to be replaced with something else, but rather augmented with new drugs that can further cajole the immune system into fighting cancer. This has led to an unprecedented amount of clinical research sponsored by drugmakers, which are combining checkpoints with other medicines to try to find a magic bullet to treat cancer. 

The sheer number of studies has sparked fears that some companies are engaging in a medical gold rush, hoping to chance upon the right cocktail without doing the appropriate scientific groundwork. 


Almost 800 clinical trials involving a checkpoint are under way in the US, according to a government database, more than 700 of which are testing the drugs in combination with one or more additional medicines. This compares with about 200 in 2015.

Some investors are unnerved by such haste, says Brad Loncar, who runs an exchange-traded fund focused on immunotherapy: “People are concerned there is not as much scientific rigour as there should be.” 

Pascal Soriot, chief executive AstraZeneca, which is trialling its own immunotherapy combination, admitted as much in a recent interview with the Financial Times. 

“The field is very competitive. Right now you have a lot of companies that take bets . . . without a lot of data,” he said. “So we also have to consider the speed, and sometimes we’re going to have to take educated risks with maybe not as much conviction or data to support the clinical programme, but enough of it.” 

While Mr Loncar believes that the recent surge in clinical trials is fundamentally a good thing for patients, he says the field should move at a speed that allows scientists to fully understand the reasons behind a particular success or failure. 

“When trials fail there’s not enough time or effort to look at the details to understand why things are not working,” he says. 

With five checkpoints on the market, the class of medicines is well-established, but many drugmakers are nonetheless developing their own versions, such as Novartis, Eli Lilly and Regeneron. In total, there are roughly 50 of these medicines, pejoratively known as “me too” products, in the pipeline. 


Some executives say the latecomers may find it increasingly difficult to fill their trials with “naive” patients who have not already been treated with a checkpoint. Many will have taken the drugs already, either because they have completed one of the hundreds of existing studies, or because their doctor has prescribed the medicine to them on an “off-label” basis, whereby they are given an immunotherapy to treat a cancer for which it is not approved.

“The level of pre-treatment and controlling for that is something we want to be cognisant of, because we want to ensure we have a consistent set of baseline patients to evaluate,” says Vas Narasimhan, global head of drug development at Novartis. “And I would say that’s getting more complex.” 

Theoretically, it should not be difficult to recruit participants given that only 4 per cent of cancer patients end up on a trial in the US. But the pharma industry has struggled to widen the pool beyond highly educated people who live in urban centres. 

Patients can also be reluctant to enter a randomised trial because they might end up in the control group that does not receive the drug, a fear that some companies have tried to assuage by allowing people to cross over into the treatment arm once their cancer worsens. Designing trials in this way can cloud the results significantly, however. 


Dr Roger Perlmutter, the top scientist at Merck, has little sympathy for laggard companies, arguing they should instead focus their efforts on unearthing new drugs or looking for biological clues that might predict which patients are most likely to respond. 

“It’s going to be difficult for those who are coming in late, but really that’s the way it should be,” he says. “The world doesn’t need any more [checkpoints]. We need other things. We should be finding a way to develop other medicines beyond these.” 

And some investors fear that the proliferation of checkpoints could end up commoditising one of the most promising drug classes in years. 

The rush to develop so many “me-too” drugs is best explained by the widely held belief that checkpoints will form the backbone of combination immunotherapies in the future. 

Those companies without their own in-house versions will have to strike deals with a rival company every time they discover a promising molecule that might be used in a cocktail, reducing their flexibility and wasting time in a highly competitive field. 

“We fully recognise there are others out there, but we decided to develop our own because we felt it was a necessary ingredient,” says Dr Israel Lowy, a vice-president at Regeneron. “We wanted the flexibility to trial it in combinations.” 

He adds: “There is a lot of room to improve if we do come up with the right combination. That’s the future. We are only at chapter one in the book of immunotherapy.” 

FT : EU considers tough new competition powers

EU considers tough new competition powers
Watchdog wants to to intervene earlier in potential antitrust cases

The EU’s competition watchdog is considering tough new powers to intervene earlier in antitrust problems in an effort to avoid the type of delays it faced in the Google investigation.

Margrethe Vestager, the EU’s competition commissioner, told the Financial Times she was looking at broader powers to impose so-called interim measures, which order companies to cease suspected anti-competitive behaviour even before there is a formal finding of wrongdoing. 

“The French have been very successful in doing interim measures for quite some time and that is, of course, of interest to us,” said the commissioner. 

A move by the European Commission to adopt such powers would give the world’s most active antitrust authority a much wider range of options to impose itself on dominant companies and shape behaviour in fast-moving markets such as the digital sector. 

The commission at present must prove a company is causing “irrevocable harm” before imposing “interim measures” — a high threshold that means it is virtually impossible to use. 

“If you have a tool in the toolbox of interim measures then of course you should consider why is it that it’s never used,” said Mrs Vestager. 

The commission is watching other jurisdictions to learn how to have a “more workable” tool. “To boil it down, it’s not being used because of the very, very high bar of irreparable harm,” she added. 

However, there were no concrete plans to change the rules just yet. She said the commission “had a lot of thinking to do” and was still trying to be “rather thorough than quick in this”.

Comparison shopping rivals had asked EU authorities to intervene to stop Google’s behaviour years ago, at a much earlier stage in the commission’s eight-year probe into the search giant.

Some rivals claim they were run out of business during the years it took to reach a decision, saying the abusive behaviour drained their sites of traffic, revenue and investment. 

Brussels has gradually attempted to strengthen the legislative framework for antitrust enforcement, but big changes are rare. New EU regulations came into force this year that gave parties additional powers to seek damages based on antitrust decisions. 

Mrs Vestager pointed out that anyone who had suffered damage from Google’s illegal behaviour could “claim compensation from Google before national courts” when she announced her decision to fine Google €2.4bn. “So, this decision requires Google to change the way it operates and face the consequences of its actions.”

Also under consideration is a new merger threshold that would require companies to seek European approval for acquisitions where the price paid was over a certain amount. Currently companies only need to seek approval for a deal when both generate sufficient sales in the EU. 

“We had a public consultation on, among other things, merger thresholds working from the hypothesis that we may have a merger that does not meet our thresholds because turnover has not showed yet, but you still have a very valuable company because of the potential of data and how it will work in the future,” said Mrs Vestager. 

German authorities have put in place a new rule to examine takeovers of companies active in the country where the price is more than €400m. The commission is watching Berlin closely and evaluating the responses to its public consultation on merger control that ended in January. 

“It is a very good thing for us to see what works well in member states, both when it comes to merger thresholds but also, for instance when it comes to the use of interim measures,” said the commissioner.

NY Post : Verizon rumored to be eyeing purchase of Disney

Verizon rumored to be eyeing purchase of DisneyVerizon rumored to be eyeing purchase of Disney

Verizon Communications’ Lowell McAdam could be hiking the Sawtooth Mountains in Sun Valley next week, perhaps in search of his next deal now that the phone company closed its acquisition of Yahoo.

One rumor making the rounds last week was that Verizon may be eyeing a Disney purchase. While that sounds fantastical, a well-placed banker told On the Money not to count Verizon out.
“It feels like Verizon is playing checkers while AT&T is playing chess,” said one media observer, reflecting the view that Verizon needs more content assets to shore up its mobile ad ambitions.

Meanwhile, AT&T CEO Randall Stephenson, who is bagging Time Warner, is also slated to attend Allen & Co.’s annual Sun Valley mogulfest, along with Time Warner’s CEO Jeff Bewkes and his three divisional chiefs: John Martin, Richard Plepler and Kevin Tsujihara.

The three amigos will be part of AT&T’s Dallas-headquartered telecom universe come fall. We’d love to hear if the gang goes whitewater rafting together in Sun Valley and what news they’ll discuss.

The high-octane deal-making powwow will be absent Disney CEO Bob Iger, Twitter boss Jack Dorsey and former Uber chief Travis Kalanick.

They’re not on the attendee list, though they could always just show up. In the case of Kalanick, however, we hear the Allen & Co. hosts are very buttoned up and do not tolerate bad-boy behavior from those on the invite list — hence his absence.

There’s a sprinkling of businesswomen on the attendee list this year: Sara Blakely of Spanx, GM’s Mary Barra and IBM’s Virginia Rometty.

Could Barra be in the driver’s seat and headed to replace Kalanick at Uber? On the Money hears she is certainly a candidate. Tipsters also shared that ViaSat, a global broadband company that among other things is used to “empower international war fighters on the front lines of battle,” will be part of the new tech breed lined up to present.

>>> What to look at this week end - 1st & 2nd of July 2017

Weekly Performance
Dow -0.21% S&P -0.61% Nasdaq -1.99% Russell +0.04% Nikkei -0.49% (-1.48% in $) Hang Seng +0.37% CSI +1.21% Shanghai +1.29% EuroStoxx -2.87% (-0.86% in $) FTSE -1.50% (+0.89% in $) CAC -2.76% Dax -3.21% Ibex -1.75% MIB -1.20% SMI -1.39%
An aggressive backup in global interest rates headlined a week that also saw a significant rebound in oil prices and bifurcated trading in US stocks. Hawkish central bank commentary complemented hotter than expected CPI readings in Europe, which induced a mid-week rotation out of sovereign bond markets, driving up yields. The spread between European and US Treasury yields narrowed, pressuring the Dollar Index, and pushing the Euro to a 1-year high. Higher rates and encouraging CCAR announcements powered equity flows into the banks and financials. In Washington, doubts about the fate of the Senate healthcare bill injected more uncertainty about the Republican legislative agenda, as GOP leaders continued to woo votes from their own caucus and were forced to push back the vote until after the 4th of July break. 
By Friday, WTI crude extended to a 7-day winning streak, adding 6.5% on the week, and buoyed equity flows. Despite the positive sentiment in those sectors, continued aggressive selling in the high beta, high profile technology stocks resulted in another notable spike in NASDAQ volatility, allowing for a mid-week dip in US stock trade. Much of the equities weakness was blamed on the likelihood that algorithmic trading along with thin quarter end/holiday conditions exacerbated a rotation out of big-cap tech into other areas of the stock market. Ultimately, stock indices were lower on the week, with the DJIA off 0.2%, the S&P500 down 0.6%, and the Nasdaq falling 2%.


Macro :
- EU’s Vestager Says Received No U.S. Reaction to Google Fine
- Emerging-Market Assets Trim Biggest Rally Since 2009: Inside EM
- Hedge Funds Cut Nasdaq Futures Holdings to 12-Month Low: CFTC

Keep an eye on :
- AMUN FP : Amundi to Expand Its Business Via ’Organic Growth,’ Sole Reports
- BA/ LN : BAE Systems Wins GBP3.7b Ship Deal From U.K. Defence Ministry
- BAYN GY : Bayer Warning Has Mosaic, Compass, Agrium Read-Through: Stifel
- BBVA SM : BBVA Frances Offers up to 95m Shares; Indicative Price: $6.23
- DEDRL IT : Delek Drilling Says Tamar Reserve 13% Bigger Than Pvs Estimate
- DROPBOX IPO : Dropbox Said to Be Seeking to Hire IPO Underwriters: Reuters
- ELAL IT : El Al Agrees on Terms to Merge Its Sun D’Or Unit With Israir
- EOAN GY : E.ON CEO Teyssen Rejects SPD Proposal to Cap Salaries: Focus
- GTO NA : Gemalto’s Potential Deal Could Be Valued Up To EU75/Share: UFP
- GSK LN : GSK Signs Drug Discovery Collaboration Deal With Exscientia
- GOOG US : Alphabet Says EU Antitrust Fine to Cut Profit by $2.74b
- LISN VX : Lindt’s Russell Stover Plans Stevia Chocolate in U.S., SamW Says
- OPTI BB ; Option Targets Up To EU9M in Revenue for 2017, De Tijd Says
- RNO FP : Renault Samsung to Recall 62,000 Cars Over Sensor Defects
- SBRY LN : Sainsbury May Be Interested in Supply Deal With McColl’s: Mail
- SRT3 GY : Sartorius Has EU1.5 Bln Leeway for Acquisitions, CFO Tells BZ
- STL NO : Statoil Evaluating New Co2 Storage Project Offshore Norway
- TELE2 SS : Tele2 Says Court Rejects Its Claim for Interest Deduction
- TKA GY : Thyssenkrupp, Tata Seek Clarity on Steel Merger This Month: HB
- TKO FP : Tikehau Must Pay EU0.28m in French Markets Regulator Probe
- FP FP : Iran, Total to Sign S. Pars Gas-Field Deal on Monday: Official
- UN01 GY : Uniper Could Invest in Sweden Reactor After Tax Agreement: CEO
- VWS DC : Vestas Gets 200-Megawatt Order in U.S.; Total 2Q Orders 1,956 MW
- VOW3 GY : Volkswagen to Recall 385,000 Cars in Germany: Bild
- VOW3 GY : VW’s France Sales Numbers Were Falsified for Years, Spiegel Says

>>> Barrons weekend summary: Positive on BMY, CELG, HEI, AABA ; Cautious on NVDA

Barrons weekend summary: Positive on BMY, CELG, HEI, AABA ; Cautious on NVDA, INTC, IRBT, TXN, Central Banks & Bitcoin 
* Cover story: Cryptocurrencies such as Bitcoin are thriving despite the fact they are barely recognized by the SEC; “Even if Bitcoin ultimately falls apart or crashes, its underlying technology—known as ‘blockchain’—is likely to disrupt financial markets for years to come”; 

* Tech Trader: Cautious on INTC, NVDA: A revolution in the chip industry could upend established players as companies such as GOOGL, which have never been involved in semiconductors, become their own chip houses and numerous startups bring fresh competition. 

* Trader: After leading the market higher this year, tech stocks are slowing down, but that doesn’t mean the Nasdaq’s rally is over; The acquisition of SPLS by private equity firm Sycamore Partners won’t put an end to troubles in the retail sector; Cautious on IRBT: Company faces headwinds from rivals Ecovacs and SharkNinja, and shares could fall to a multiple more in line with other appliance vendors. 

* Profile: Christopher Beck of the Delaware Small Cap Value fund focuses on cash flow and capital spending and is leery of companies with too much debt (top 10 holdings: EWBC, BERY, MTZ, SNPS, SIGI, HBHC, WBS, OLN, TSE, FUL). 

* Interview: Evan Lorenz of Grant’s Interest Rate Observer says he isn’t finding as many cheap, defensible longs with good balance sheets that the publication can recommend (pick: Fibra Uno; pans: KHC, WHR, Canadian Apartment). 

* Features: 1) Bitcoins are a speculative investment, and there are number of ways to invest in them, though no U.S. exchange-traded funds track them; Michael Novogratz, formerly of Fortress Investment Group, says the market cap could reach $5T in five years, up from $42B today; 2) Positive on BMY: Shares of company are down on disappointing trials, but investors are ignoring lucrative potential markets, and the shares could return 25-40% during the next two to three years; 3) Cautious on TXN: Though the stock’s price/earnings ratio remains near a historical average, shares are up 25% and could rise another 20% or more based on strong margins, high cash flow, and dominant market positions; 4) The cable and wireless sectors are likely to see a round of dealmaking among all but market leaders Comcast and CHTR, and one or more cross-industry combinations appear likely. 

* Small Caps: Positive on HEI: Company that provides replacement parts for the airline industry has thrived for more than 50 years, and its earnings and stock price should compound at a mid-teens rate in coming years. 

* Follow-Up: Positive on CELG: Pharma sees the potential for $21B in yearly revenue, nearly double what it booked last year, if results from 17 late-stage trials are positive; Positive on AABA: Shares trade at a 30% discount to the value of the company’s assets, and investors could benefit from catalysts such as tax reform or aggressive share repurchases. 

* European Trader: Positive on Sanne Group: Fund-administration outsourcing firm is tapping into the lucrative market of managing the myriad regulatory demands faby financial services companies. 

* Asian Trader: Beijing’s move to open the Shanghai and Shenzhen stock connect platforms has undercut Hong Kong’s big selling point as an intermediary for foreign investors in China. 

* Emerging Markets: “Emerging market debt, which boasts an average yield of about 6%, has had record inflows and healthy returns this year,” and the trend is likely to continue over the next seven years. 

* Commodities: Some market pundits think a falling dollar and global political turmoil could give gold a boost in the second half of the year. 

* Streetwise: Story says the era of extraordinary central bank support—the result of which is record-high stock and bond prices, but modest economic growth—may be about to end.

(ZH) The Swiss National Bank Owns $80 Billion In US Stocks - Here's The Catch

The Swiss National Bank Owns $80 Billion In US Stocks - Here's The Catch
Switzerland is a small country of just 8 million people, but they make an outsized impact on economics and finance and money.

Because Switzerland is considered a safe haven and a well-run country, many people would like to hold large amounts of their assets in the Swiss franc. This makes the Swiss franc intolerably strong for Swiss businesses and citizens.


So the Swiss National Bank (SNB) has to print a great deal of money and use nonconventional means to hold down the value of their currency. Their overnight repo rate is -0.75%.

That’s right, they charge you a little less than 1% a year just for the pleasure of letting your cash sit in a Swiss bank deposit.

Switzerland Is Buying US Stocks on an Enormous Scale


And the SNB is buying massive quantities of dollars and euros, paid for by printing hundreds of billions in Swiss francs.

The SNB owns about $80 billion in US stocks today (June, 2017) and a guesstimated $20 billion or so in European stocks (this guess comes from my friend Grant Williams, so I will go with it).

They have bought roughly $17 billion worth of US stocks so far this year. And they have no formula; they are just trying to manage their currency.

Think about this for a moment: They have about $10,000 in US stocks on their books for every man, woman, and child in Switzerland, not to mention who knows how much in other assorted assets, all in the effort to keep a lid on what is still one of the most expensive currencies in the world.

Switzerland is now the eighth-largest public holder of US stocks. It has got to be one of the largest holders of Apple.

What Happens When There Is a Bear Market?
Who bears the losses?

Print just more money to make up the difference on the balance sheet? Do we even care what the Swiss National Bank balance sheet looks like? More importantly, do they really care?

We all remember European Central Bank President Mario Draghi’s famous remark, that he would do “whatever it takes” to defend the euro. We could hear the Swiss singing from the same hymnbook soon.

Central Banks and Governments Exacerbate the Bubble
The point is that central banks and governments are flooding the market with liquidity all over the world.

That’s showing up in the private asset markets, in stock and housing and real estate and bond prices. It creates an unquenchable desire for what appear to be cheap but are actually overvalued assets—which is what creates a Minsky moment.

Now, remember what Minsky said: When an economy reaches the Ponzi-financing stage, it becomes extremely sensitive to asset prices. Any downturn or even an extended flat period can trigger a crisis.

While we have many domestic issues that could act as that trigger, I see a high likelihood that the next Minsky moment will propagate from China or Europe. All the necessary excesses and transmission channels are in place.

The Great Reset Is Close
The hard part, of course, is the timing. The Happy Daze can linger far longer than any of us anticipate. Then again, some seemingly insignificant event in Europe or China—an Austrian Archduke’s being assassinated, or what have you—can cause the world to unravel.

It’s a funny world.

Our central banks and governments exhibit unmistakable herd behavior and continue to do the same foolish things over and over. They never really intend to have the crisis that ensues.

Remember Farrell’s Rule 3: There are no new eras. The world changes, but danger remains. Gravity always wins eventually. It will win this time, too. And when it does, we will begin to undergo the Great Reset.

WSJ : Wall Street Strategists Forecast Most-Bearish Second Half Since 1999

Telecom Argentina, Cablevisión Announce Merger
Announcement from Argentina’s leading internet service providers comes ahead of the opening of the country’s telecommunications sector next year

BUENOS AIRES— Telecom Argentina TEO 3.56% and Cablevisión, two of Argentina’s leading telecommunications and internet service providers, said they plan to merge ahead of the opening of the country’s telecommunications sector next year.
The merger, announced late Friday, would allow the companies to offer so-called quadruple play services, including fixed-line and mobile communications as well as broadband and television programming. The deal, approved by the boards of both companies, would have to be approved by shareholders and regulators
“The combination of the two companies will strengthen their investment in modern, mobile technology infrastructure as well as the build out of a high speed fiber optic network,” Telecom Argentina said in a statement.

Telecom Argentina is owned by Fintech Advisory, a firm run by David Martínez, a Mexican-born investor who already holds a 40% stake in Cablevisión.
News of the merger comes six months ahead of Argentina’s plan to allow companies here to offer quadruple play services, which have been largely prohibited in Argentina.
It also comes ahead of a key midterm congressional election in October in which former President Cristina Kirchner will compete for a Senate seat. Mrs. Kirchner’s government heavily regulated the media and telecommunications industry, passing a landmark law that put new limits on media companies, particularly Grupo Clarín ,which holds a 60% stake in Cablevisión.
Mrs. Kirchner portrayed Grupo Clarín as an all-too-powerful political actor that needed to be downsized to give competing media outlets greater influence. Grupo Clarín has said the Kirchner administration was trying to muzzle independent media.
Media regulation is a politically charged topic in Argentina and any move by regulators to approve the merger could become political fodder during the congressional campaign. Analysts say the election will be seen as a referendum on the more market friendly policies of Mrs. Kirchner’s market-friendly successor, Mauricio Macri.
President Macri says Mrs. Kirchner’s media policies stymied investment and favored companies that promoted her agenda. Indeed, her administration distributed a disproportionate amount of state funding to media outlets that offered her favorable coverage. Mr. Macri has moved to boost investment in the sector and is trying to woo foreign companies.
The merger would provide the companies with a roughly 55% market share in broadband services, according to Enrique Carrier, an industry analyst. It would also pose a challenge to Claro, a unit of Mexico’s América Móvil SAB , and the local unit of Spain’s Telefónica SA .

“This implies the creation of a single company capable of offering quadruple play and it will also be a player which is strong in each of those services,” Mr. Carrier said. “That would give the company a dominant position in broadband and give it an advantage over competitors such as Telefónica, which doesn’t offer television services and Claro, which doesn’t have a broadband network."

(ZH) Wall Street Strategists Forecast Most-Bearish Second Half Since 1999

Wall Street Strategists Forecast Most-Bearish Second Half Since 1999


Despite a hiccup in the last week or so, global stocks survived as the best-performing asset class of the year (with the MSCI All-Country World Index wrapping up its best first half in 19 years)...
But, as Bloomberg reports, Wall Street strategists are fighting historic odds when urging investors not to chase the rally in the U.S. stock market.

They’re predicting the S&P 500 Index will see momentum fade in the second half after shares climbed 8.2 percent for the best first-half performance since 2013.

The average year-end prediction, 2,439, represents a 0.6 percent increase by December, the least bullish forecast at this time of year since 1999, data compiled by Bloomberg show.
Among the 20 strategists surveyed by Bloomberg, stretched valuations and decelerating profit growth are often cited as reasons for caution. Yet stocks have shrugged off everything from monetary tightening to oil’s slump to drama at the White House, surging past Wall Street forecasts that at the start of the year were the least bullish in more than a decade.
Of course there are always those who remain serial extrapolators...


Laszlo Birinyi, a steadfast bull during the eight-year equity rally, said the prevailing caution among strategists is one reason why he’s optimistic. The president of Birinyi Associates Inc. recently said his firm would buy calls betting on the S&P 500 to reach 2,500 by September.

“Wall Street continues to be unenthusiastic regarding the market,” Birinyi wrote to his clients this week. “New highs are generally greeted with a yawn. Especially encouraging is the fact that investors have cash,” he said. “As the year proceeds, we are actually feeling better about the market.”
Others are sticking to bearish calls.


Tom Lee, Fundstrat Global Advisors co-founder who’s the most bearish with a prediction of 2,275, last week slashed his S&P 500 earnings forecasts for this year and next, citing weaker inflation, rising labor costs and a delay in President Trump’s growth agenda.
And while VIX just had its biggest intraday surge since last year’s Brexit vote result, it just posted its second quarterly decline, with a 7.5% drop. The VIX came within 5% of its record low earlier in June and averaged 11.4 in the past three months, the lowest quarterly average since 2006.

And it is not just US equities that are concerning, the cost to hedge against European stock swings just saw its biggest monthly surge since January 2016.
The VStoxx Index jumped 21 percent in June, reaching its highest level since before the French election in April. The Euro Stoxx 50 Index is poised for a quarterly decline on growing speculation the region’s central banks will tighten policy -- something that would likely trigger market turmoil in the medium term, JPMorgan said.
Of course Wall Street strategists aren't alone in their skepticism of US equity exuberance...
"Transitory"

FT : Daniel Loeb: Master of the universe makes a comeback

Daniel Loeb: Master of the universe makes a comeback

The surf-loving founder of Third Point now has Europe in his sights

At a lavish annual hedge fund conference in Las Vegas that attracts some of the biggest players in the industry, a familiar name was on the agenda earlier this year. But unlike in previous years, this time there was a stipulation: Daniel Loeb would be speaking off the record.

Mr Loeb, the 55-year-old sharp-tongued activist investor and founder of Third Point, is not usually one to censor himself. Two years earlier, at the same conference, he took a swipe at Warren Buffett for the “wide disconnect” between what he practices and preaches regarding hedge funds.

He has sued Sotheby’s, the auction house, helped oust the chief executive of Yahoo and publicly targeted companies ranging from Dow Chemical to Sony. But Mr Loeb’s latest investment, a stake in Nestlé worth about $3.5bn, reflects the more tempered persona that the once-fiery investor has adopted of late. There were no angry letters to the board or demands for inept management to step down. The stake was announced in a letter to Third Point investors earlier this week with a list of requests: the Swiss food group should sell its remaining 23 per cent shareholding in L’Oréal; boost its debt to buy back shares; and set a formal profit margin target of 18 to 20 per cent by 2020. Many of those may have already been set in train by Nestlé chief executive Mark Schneider, who is still in his first year in the role and is working on plans to revamp the conglomerate.


Mr Loeb, a health buff and yoga fanatic who often retweets the Dalai Lama’s inspirational quotes, has not necessarily chilled out in the third decade of his fund’s operation. Yet activism has changed as the strategy has grown commonplace. Boards are more willing to engage, so the public foot-stomping by some activists has faded, while institutional investors are more ready to vote in line with activists, and even to court them.

While Mr Loeb and investors such as Carl Icahn and Bill Ackman championed public battles with companies, a group of funds, including Europe’s Cevian Capital and San Francisco-based ValueAct, employed a “constructivist” style of activism, where they sought to engage management behind the scenes in the hopes of driving change that way. It’s an approach Mr Loeb is increasingly adopting — and one that is more commonly deployed in Europe, a region he and other activists have in their sights.


But the Nestlé stake is also the largest investment Mr Loeb has ever made, and shows that even multinational conglomerates are not immune to being targeted by activist shareholders. Third Point, which manages $18bn, raised another $1bn in a special purpose vehicle to purchase the stake.

Activism has been experiencing a resurgence in the past year after the high-profile struggles of Valeant, a US drugmaker whose shares plunged after it was targeted by activists, and Bill Ackman’s ill-fated campaign against Herbalife had led some investors to go sour on the strategy.

Mr Loeb, too, has been making a comeback. After his fund returned more than 20 per cent in 2012 and 2013, returns fell to 5.7 per cent in 2014 and were down 1.4 per cent in 2015 and returned 6.1 per cent last year. But Third Point’s master fund was up 10 per cent at the end of May and assets have returned to a previous peak of $18bn.

Mr Loeb, who is estimated to be worth about $2.9bn, started his fund in 1995 in the weight room of David Tepper, the founder of the hedge fund Appaloosa Management, with a desk he found on the side of the road and a few million he raised from family and friends.

Born in 1961 in Santa Monica, California, to a high-powered lawyer and a historian, Mr Loeb always seemed to have an entrepreneurial streak. In high school, he started a skateboard company called “B Industries”. He attended the University of California at Berkeley before graduating from Columbia University in New York with a degree in economics. He cycled through jobs in finance over a decade from the mid-1980s to mid-1990s, first at the private equity firm Warburg Pincus, then in corporate development at the record label Island Records, and later at Jefferies and Citigroup.

In the pantheon of masters of the universe, Mr Loeb is one of the more colourful — an avid surfer who has cited the rapper Tupac in his investment letters and once challenged a group of former navy Seals to a half iron triathlon to raise money for charity. When Third Point celebrated its 20-year anniversary in 2015, its invitation letters featured a younger Mr Loeb on the cover of a fake rap album entitled “2 Legit 2 Quit”.

He is married with three children and reportedly spent a then-record-breaking $45m in 2005 on an Upper West Side penthouse. He also owns a yacht he bought from former Citigroup chief executive Sandy Weill and a palatial home in East Hampton.

With the Nestlé stake, Mr Loeb has also shown his readiness to tackle Europe as opportunities in the US dwindle. People close to Third Point say the fund is increasingly looking towards the continent as the eurozone stabilises following the election of Emmanuel Macron in France.

But Mr Loeb has been burnt before when wandering into new territory — for example in Japan, where he targeted Sony, proposing that the company split in two. But Sony did not heed his demands and the share price continued to fall. Nevertheless, Third Point sold the stake at a profit in late 2014.